Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bridging Efficacy of Tofacitinib Immediate-Release to Extended-Release Formulations for Treatment of Ulcerative Colitis: Application of a Model-Informed Drug Development Approach.
Mukherjee A, Tsuchiwata S, Chang C, Nicholas T, Su C, Le VH, Kushner J, Kulisek N. Mukherjee A, et al. Among authors: le vh. Clin Pharmacol Drug Dev. 2022 Aug;11(8):976-986. doi: 10.1002/cpdd.1106. Epub 2022 May 13. Clin Pharmacol Drug Dev. 2022. PMID: 35560874 Free PMC article.
Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs.
Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, David Rodrigues A, Muto C, Furihata K, Sugiyama Y, Kusuhara H. Mori D, et al. Among authors: le vh. Clin Pharmacol Ther. 2020 Apr;107(4):1004-1013. doi: 10.1002/cpt.1695. Epub 2020 Jan 1. Clin Pharmacol Ther. 2020. PMID: 31628668 Free PMC article. Clinical Trial.
Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein-Mediated Drug-Drug Interactions in Healthy Volunteers.
Miyake T, Kimoto E, Luo L, Mathialagan S, Horlbogen LM, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, Rodrigues AD, Muto C, Furihata K, Sugiyama Y, Kusuhara H. Miyake T, et al. Among authors: le vh. Clin Pharmacol Ther. 2021 Feb;109(2):507-516. doi: 10.1002/cpt.2022. Epub 2020 Oct 9. Clin Pharmacol Ther. 2021. PMID: 32866300 Free PMC article. Clinical Trial.
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Wang X, Dowty ME, Wouters A, Tatulych S, Connell CA, Le VH, Tripathy S, O'Gorman MT, Winton JA, Yin N, Valdez H, Malhotra BK. Wang X, et al. Among authors: le vh. Eur J Drug Metab Pharmacokinet. 2022 May;47(3):419-429. doi: 10.1007/s13318-021-00745-6. Epub 2022 Feb 28. Eur J Drug Metab Pharmacokinet. 2022. PMID: 35226304 Free PMC article.
140 results